Key statistics
On Monday, Nuvalent Inc (NUVL:NSQ) closed at 84.59, -25.48% below its 52-week high of 113.51, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 80.82 |
---|---|
High | 84.75 |
Low | 80.02 |
Bid | 80.30 |
Offer | 88.96 |
Previous close | 80.93 |
Average volume | 449.71k |
---|---|
Shares outstanding | 71.81m |
Free float | 60.78m |
P/E (TTM) | -- |
Market cap | 5.81bn USD |
EPS (TTM) | -4.40 USD |
Data delayed at least 15 minutes, as of Jul 14 2025 21:00 BST.
More ▼
- Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
- Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
- Nuvalent Appoints Christy Oliger to Board of Directors
- Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
- Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
- Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
More ▼